Enrolment reaches 50% in Lynovex CARE-CF-1 trial


NovaBiotics Ltd (NovaBiotics) this week reached a key milestone in its CARE-CF-1 clinical study with 60 subjects, out of an expected 120, now randomised.


(NBTCS-02) investigating oral Lynovex® as an adjunct therapy in Cystic Fibrosis (CF) infectious exacerbations with half of the required patients now randomised. Subjects have now been dosed in several sites across the UK, US & Italy.


The randomised, placebo controlled double blind study follows promising preliminary Phase IIa data for NovaBiotics’ orphan drug candidate.  The current trial aims to assess the benefits of oral Lynovex®, the hard gel capsule form of the drug, as adjunct therapy to standard of care antibiotic and other interventions in CF infectious exacerbations.


NovaBiotics are very grateful to all those involved in helping us reach this milestone.